Squarepoint Ops LLC cut its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 11.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 532,321 shares of the company's stock after selling 71,679 shares during the period. Squarepoint Ops LLC owned approximately 0.87% of Janux Therapeutics worth $8,176,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the business. Rhenman & Partners Asset Management AB increased its holdings in shares of Janux Therapeutics by 125.1% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 225,377 shares of the company's stock valued at $3,110,000 after acquiring an additional 125,250 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Janux Therapeutics in the 1st quarter worth approximately $1,946,000. Bank of New York Mellon Corp bought a new stake in Janux Therapeutics during the second quarter worth approximately $2,075,000. Rangeley Capital LLC boosted its position in Janux Therapeutics by 382.0% during the first quarter. Rangeley Capital LLC now owns 122,500 shares of the company's stock worth $1,703,000 after purchasing an additional 97,086 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Janux Therapeutics during the second quarter valued at approximately $739,000. 75.39% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
JANX has been the topic of a number of recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Guggenheim lowered their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Wolfe Research upgraded shares of Janux Therapeutics from a "peer perform" rating to an "outperform" rating and set a $23.00 target price on the stock in a report on Monday, August 24th. TD Cowen upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Finally, Truist Financial reissued a "buy" rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $36.46.
Read Our Latest Stock Analysis on JANX
Janux Therapeutics Trading Down 8.5%
Shares of JANX stock opened at $17.68 on Friday. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34. The company has a market capitalization of $1.08 billion, a P/E ratio of -10.78 and a beta of 2.53. The stock has a 50 day moving average of $16.91 and a two-hundred day moving average of $15.22.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.
Janux Therapeutics Company Profile
(
Free Report)
Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.
Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.
Featured Articles
Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
